Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Notebook: Vaccine Safety Study Kicks Off In UK, Govt Plans Booster Vaccination For Most Vulnerable

Executive Summary

A new international task force has used its first meeting to call for more access to COVID-19 vaccines and therapies in developing countries, and the World Bank and other finance institutions are putting money into South African firm Aspen Pharmacare to boost the production of vaccines.

You may also be interested in...



Africa Vaccine Supplies To Rise After ‘Worst Pandemic Week Ever’

Despite an alarming surge in coronavirus cases across the African continent, there are hopes of a substantial rise in vaccine supplies in the coming months.

Coronavirus Notebook: South Africa To Build mRNA Vaccine Tech Transfer Hub, EMA OKs More Comirnaty Production Capacity

MSF is pressuring Moderna and Pfizer/BioNTech to share their vaccine know-how with manufacturers in developing countries, and companies have just a few days to answer the European Commission's questions about COVID-19 therapies they have in development.

Coronavirus Notebook: EU Agencies Update On ‘Mix-And-Match’ & Booster Vaccines, UK Expands Human Challenge Trial

ExeVir’s potential antibody therapy against variants of concern is moving into clinical trials, and Irish researchers say an abandoned glioblastoma candidate compound could prevent respiratory and cardiovascular damage in COVID-19 patients.

Topics

UsernamePublicRestriction

Register

PS144573

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel